Hypoimmune & In Vivo Delivery Platforms to Enable Off-The-Shelf CAR-T Cell Therapies

Time: 9:30 am
day: Day One


  • The complexities in manufacturing autologous products limits access to highly effective CAR-T cell therapy
  • Allogeneic T-cells manufactured using Sana’s hypoimmune technology evade both innate and adaptive immunity
  • Sana’s gene delivery platform efficiently generates a functional CAR-T cell in vivo